Minerva Neurosciences to Host Key Opinion Leader Meeting on the Negative Symptoms of Schizophrenia on Thursday, March 22
March 15 2018 - 8:30AM
WALTHAM, Mass., March 15, 2018 (GLOBE
NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq:NERV), a
biopharmaceutical company focused on the development of therapies
to treat central nervous system (CNS) disorders, today announced
that it will host a Key Opinion Leader (KOL) meeting on the topic
of Negative Symptoms of Schizophrenia on Thursday, March 22, 2018
in New York City.
The event will feature presentations by KOLs Ofer
Agid, MD, Centre for Addiction and Mental Health, University of
Toronto, and Thomas Laughren, MD, former Division Director,
Division of Psychiatry Products, CDER, who will discuss the current
pharmacological treatment strategies to address positive and
negative symptoms of schizophrenia, as well as the regulatory path
for novel compounds that address negative symptoms. Both Dr. Agid
and Dr. Laughren will be available to answer questions at the
conclusion of the event.
Members of Minerva's management team will further
discuss the evolving paradigm in the diagnosis and pharmacological
treatment of negative symptoms in schizophrenia and beyond. They
will review the clinical development of roluperidone (MIN-101) for
the treatment of negative symptoms of schizophrenia and the design
of the Phase 3 clinical trial with this compound.
Dr. Agid is a Clinician Scientist and Psychiatrist
in the Schizophrenia Program and Medical Leader of the Home
Intervention for Psychosis (HIP) team at the Centre for Addiction
and Mental Health. He is also Associate Professor in the Department
of Psychiatry at the University of Toronto. Dr. Agid's research
focus is psychopharmacology in schizophrenia, specifically early
response to antipsychotic medications and early predictors of
response. His work has uncovered a new "early onset of action"
hypothesis of antipsychotics, which has impacted current practice
guidelines for the treatment of schizophrenia. As the medical
leader of the HIP team, Dr. Agid initiated an algorithm-based
treatment approach for first-episode schizophrenia while collecting
extensive clinical data regarding treatment response. This
algorithm was implemented in order to optimize antipsychotic
treatment during the earliest stages of the illness, a critical
time period in terms of longer-term outcomes. This systematic and
standardized approach has resulted in a large and comprehensive
database; the published data to date have provided clear, empiric
evidence that clinicians can use in approaching the pharmacological
management of first-episode schizophrenia. It has also challenged
current practice patterns and proven valuable in examining
trajectories of response. In addition, Dr. Agid is involved in
investigating patterns of non-adherence and examining value systems
and happiness in schizophrenia, with an emphasis on the
relationship to, and influence on, functional outcomes.
Dr. Laughren is currently a consultant in
psychiatric drug development. He recently retired as Division
Director for the Division of Psychiatry Products, Center for Drug
Evaluation and Research at FDA. Prior to joining FDA in September,
1983, Dr. Laughren was affiliated with the VA Medical Center in
Providence, RI, and was on the faculty of the Brown University
Program in Medicine. He received his medical degree from the
University of Wisconsin in Madison, Wisconsin, and also completed
residency training in psychiatry at the University of Wisconsin.
Dr. Laughren is board certified in general psychiatry. As Division
Director for the Division of Psychiatry Products, Dr. Laughren
oversaw the review of all psychiatric drug development activities
conducted under INDs and the review of all NDAs and supplements for
new psychiatric drug claims. He has authored and co-authored many
papers and book chapters on regulatory and methodological issues
pertaining to the development of psychiatric drugs and is a
frequent speaker at professional meetings on these same topics. Dr.
Laughren has received numerous awards for his regulatory
accomplishments.
This event is intended for institutional
investors, sell-side analysts, investment bankers, and business
development professionals only. Please RSVP in advance if
you plan to attend, as space is limited. For those who are
unable to attend in person, a live webcast and replay of the event
will be accessible here.
About
Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage
biopharmaceutical company focused on the development and
commercialization of a portfolio of products to treat CNS
diseases. Minerva`s proprietary compounds include:
roluperidone (MIN-101), in Phase 3 clinical development for
schizophrenia; seltorexant (MIN-202 or JNJ-42847922), in Phase 2b
clinical development for insomnia and major depressive disorder
(MDD); MIN-117, planned to begin Phase 2b clinical development for
MDD in early 2018; and MIN-301, in pre-clinical development for
Parkinson`s disease. Minerva`s common stock is listed on the
NASDAQ Global Market under the symbol "NERV." For more
information, please visit www.minervaneurosciences.com.
Forward-Looking Safe Harbor
Statement
This press release contains
forward-looking statements which are subject to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995,
as amended. Forward-looking statements are statements that
are not historical facts, reflect management's expectations as of
the date of this press release, and involve certain risks and
uncertainties. Forward-looking statements include statements
herein with respect to the potential of the diagnosis and treatment
of negative symptoms in schizophrenia and other diseases; the
timing and scope of future clinical trials and results of clinical
trials; the timing and outcomes of future interactions with U.S.
and foreign regulatory bodies; our ability to successfully develop
and commercialize our therapeutic products. These
forward-looking statements are based on our current expectations
and may differ materially from actual results due to a variety of
factors including, without limitation, whether roluperidone,
seltorexant, MIN-117 and MIN-301 will advance further in the
clinical trials process and whether and when, if at all, they will
receive final approval from the U.S. Food and Drug Administration
or equivalent foreign regulatory agencies and for which
indications; whether any of our therapeutic product discovery and
development efforts will be successful; management's ability to
successfully achieve its goals; our ability to raise additional
capital to fund our operations on terms acceptable to us; and
general economic conditions. These and other potential risks
and uncertainties that could cause actual results to differ from
the results predicted are more fully detailed under the caption
"Risk Factors" in our filings with the Securities and Exchange
Commission, including our Annual Report on Form 10-K for the year
ended December 31, 2017, filed with the Securities and
Exchange Commission on March 12, 2018. Copies of reports
filed with the SEC are posted on our website
at www.minervaneurosciences.com. The forward-looking
statements in this press release are based on information available
to us as of the date hereof, and we disclaim any obligation to
update any forward-looking statements, except as required by
law.
Contact:
William B. Boni
VP, Investor Relations/
Corp. Communications
Minerva Neurosciences, Inc.
(617) 600-7376
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Minerva Neurosciences, Inc. via Globenewswire
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Mar 2024 to Apr 2024
Minerva Neurosciences (NASDAQ:NERV)
Historical Stock Chart
From Apr 2023 to Apr 2024